Genetic association studies of alterations in protein function expose recessive effects on cancer predisposition

Nadav Brandes1, Nathan Linial1 & Michal Linial2

Cancer is considered a genetic disease. Notably, that characterization typically refers to somatic mutations in tumors, not to inherited germline genetic variation. Nonetheless, like with any non-Mendelian disease, germline variants are known to contribute to cancer predisposition1. The best-known examples of cancer predisposition genes are the tumor suppressors BRCA1 and BRCA2 involved in breast and ovarian cancers2. By 2014, following thirty years of research, 114 cancer predisposition genes had been reported, mostly based on families with high prevalence of cancer3. As of 2016, the list was expanded to include genes from pediatric cancers4. Some of the genes most prevalent in children are also known cancer driver genes from the somatic context (e.g. TP53, APC, BRCA2, NF1, PMS2, RB1 and RUNX1). Recently, a based unified list of 152 cancer predisposition genes was refined on germline variants from The Cancer Genome Atlas (TCGA) across 33 cancer types5 (see also the discussion in6).

Although the heritability of most cancers is considerable7–9 and despite many years of research leading to the identification of numerous genes, the overall genetic risk explained by the discovered genes remains quite limited. It turned out that BRCA1 and BRCA2 are quite exceptional in their high penetrance, with most cancer predisposition genes showing only mild effects10–13. Notably, a gene's effect size is highly dependent on the cancer-type and population context. For example, BRCA1 and BRCA2 are mostly specific to a small set of cancer types such as breast and ovarian cancer, and are highly enriched in Ashkenazi Jews14.

In recent years, the exponential growth in genotyped cohorts and the availability of genome-wide association studies (GWAS) have allowed the discovery of additional genetic loci associated with cancer. As opposed to...
family studies, GWAS can pick genetic factors with smaller effect sizes, provided that the variants are common enough. Several years of GWAS research into cancer predisposition have implicated numerous cancer predisposition loci (e.g. in breast, lung, prostate, colorectal cancer and melanoma). It is anticipated that by increasing cohort sizes, more genetic associations will be found. Interestingly, the overlaps of significant loci in independent GWAS works studying the same cancer types tend to be surprisingly small, supporting the claim that GWAS efforts in this domain are far from saturated. Benefits from GWAS are also constrained by the lack of interpretability of most implicated loci, which do not appear to affect any functional elements in the genome.

The majority of GWAS projects are restricted to specific cancer types, limiting their capacity to draw strong conclusions about the similarities and differences between the genetic signatures of cancer types. Moreover, the collective study of all cancer types as a single phenotype, known as pan-cancer, is prevalent in the somatic world, but remains understudied in the germline context. The UK Biobank (UKB) cohort is highly suitable for comparative studies between phenotypes, due to its uniform standards and protocols applied across all samples. The UKB covers ~ 500,000 genotyped individuals with open medical records. As it recruited only individuals older than 40 years, the cohort is enriched with cancer cases.

An important limitation of GWAS is its assumption of additive genetic effects, which leads to oversight of dominant and recessive effects. This limitation is particularly relevant to recessive inheritance. While some GWAS works have modeled recessive inheritance at the variant level, this solves only a small part of the problem, as recessive effects are likely to occur at the gene level. Specifically, it is anticipated that most recessive effects would manifest through compound heterozygosity, namely different variants affecting the two copies of the same gene. Unfortunately, variant-level approaches like GWAS cannot detect genetic patterns that transcend individual variants. As attested by family studies, recessive inheritance is likely to play a major role in cancer predisposition, as in other complex traits.

Recently, we developed Proteome-Wide Association Study (PWAS), a new gene-based method that addresses many of the shortcomings of GWAS. PWAS detects gene-phenotype associations that are mediated by alterations to protein function (Fig. 1). To do so, it considers the proteomic context of genetic variants and their functional effects. As a gene-based method, PWAS aggregates the signal from all variants affecting the same protein-coding gene, and can detect genes with dominant and recessive effects. Unlike GWAS, PWAS associations are supported by concrete functional effects in coding genes, making them more interpretable.

In this work we study genetic predisposition to cancer in the UKB across 10 cancer types (including pan-cancer) using genome-wide and proteome-wide association studies, thereby providing a systematic view of genetic cancer predisposition from a protein function perspective. We compare our results to contemporary clinical knowledge about cancer predisposition and to catalogues of cancer driver genes from the somatic world. We took advantage of the capacity of PWAS to model dominant and recessive effects to systematically study the importance of these heritability modes in cancer predisposition across the human coding genome.

Results
Genetic and protein-function analysis of cancer predisposition in the UK Biobank. From the UKB, we derived a study cohort of 274,830 unrelated white individuals. Based on their medical records, we determined that 56,634 of those individuals had a history of cancer. In addition to this pan-cancer view, we also considered nine distinct cancer types: melanoma, leukemia, breast, ovarian, prostate, lung, skin, pancreatic and colorectal cancer. We studied each of the ten defined cancer types (the nine specific cancers and pan-cancer) using both GWAS and PWAS independently. With GWAS we found 883 significant variant-cancer associations in 100 unique genomic regions, and with PWAS we found 110 significant gene-cancer associations in 70 unique genomic regions. Altogether, the GWAS and PWAS associations mapped to 145 unique genomic regions, available at Supplementary Table S1. The full GWAS and PWAS results across the ten cancer types and all tested variants and genes are available at Supplementary Table S2 and Supplementary Table S3.

We compared the 145 discovered genomic regions against prominent cancer predisposition gene panels used in the clinics (CleanPlex TMB 500 and Invitae Multi-Cancer). We also compared our results to three catalogues of cancer driver genes: Census, the pan-software catalogue and FABRIC. We find that a majority of the 145 significant cancer regions are indeed supported by external evidence (clinical panels, cancer driver catalogues, or both), but 51 of the 145 regions (35%) appear as new discoveries. We also observe that external validation is slightly stronger for significant regions that are supported by both GWAS and PWAS.

Single-gene loci with direct interpretation. To demonstrate the discovered genetic signal of cancer predisposition, we begin by focusing on high-confidence associations with plausible causal mechanisms. One of the benefits of PWAS is its capacity to suggest concrete protein-coding genes underlying genetic associations. However, like GWAS, PWAS is also sensitive to linkage disequilibrium, which can lead to the genetic signal being spread across an extended genomic region and mistakenly attributed to an unrelated nearby gene. For this reason, it is of interest to examine significant associations that are restricted to single genes. We define a significant cancer region to be a soliton region if i) it has exactly one gene significant by PWAS, and ii) the significance is very strong (FDR q-value < 1E−03). Of the 145 cancer regions, 14 are solitons according to this definition (Table 1).

5 of the 14 soliton genes are supported by gene panels (CleanPlex or Invitae), and 3 of them are supported by Census and other cancer driver catalogues. Importantly, the criteria of external evidence for the solitons listed in Table 1 are stricter than those used for the genomic regions in Fig. 3. Whereas in Fig. 3 we considered evidence for any gene within the same region (which may include up to 138 genes; see Supplementary Table S1), in Table 1 we only consider evidence matching the exact soliton gene.
In addition to recovering genomic regions that are missed by GWAS, a major contribution of PWAS is highlighting the exact genes that drive known associations. Of the 14 soliton genes, 8 are also found by standard GWAS, whereas the other 6 are below the exome-wide significance threshold (5E−07). IRF3 (interferon regulatory factor 3), for example, is associated with non-melanoma skin cancer according to PWAS with overwhelming significance (FDR q-value = 7E−6), but not according to GWAS (p = 1E−6). IRF3 is part of the innate immune system, whose one of its major roles is to recognize and destroy infected and tumorous cells. In-vivo and expression studies have implicated IRF3 in melanoma38,39 and other cancer types40,41.

The list of solitons also includes novel discoveries. For example, UBE3A (ubiquitin protein ligase E3A; also known as E6AP) is known for resulting in the ubiquitylation and degradation of the p53 tumor suppressor in

---

**Figure 1.** Proteome-wide association study (PWAS). PWAS finds associations between phenotypes (such as cancer) and protein-coding genes that are mediated by genetic alterations to protein function. (A) When studying a protein-coding gene, PWAS collects all the called variants in the genome of an individual that affect the coding sequence of that protein. Using a machine-learning model, it predicts how damaging these variants are to the protein function (for example, how likely an enzyme is to retain its catalytic activity given each of the mutations, which might affect its 3D structure). It then aggregates the predictions made for all the variants into overall gene effect scores. Each gene is assigned two such scores, corresponding to either a dominant or a recessive genetic effect. The dominant effect score attempts to capture the event that the gene is affected by at least one damaging variant, whereas the recessive effect score attempts to capture the event that it is affected by at least two damaging variants. (B) Given a cohort of cases and controls, PWAS assigns each individual dominant and recessive effect scores for the studied protein-coding gene based on his or her genetics, as described in (A). By comparing the distributions of gene effect scores assigned to cases and controls, PWAS can detect statistically significant differences between the two groups (measured by p-values and FDR q-values). These differences reflect the estimated functional damage to the gene, finding, for example, that the studied protein appears to be more damaged in cases than in controls.
papillomavirus-positive cervical cancer\textsuperscript{42}, and it has also been implicated with prostate and other cancers\textsuperscript{43–45}.

**Figure 2.** Analysis workflow. From the UK Biobank cohort (~500 K individuals), we derived a study cohort of 274,830 individuals. Based on their medical records, we determined whether each of the individuals had a history of cancer, focusing on nine major cancer types and pan-cancer which combines individuals with any cancer (56,634 overall). We used two statistical methods, standard GWAS and PWAS, over each of the ten cancer types, and found 883 variant-cancer and 110 gene-cancer significant associations, respectively. We merged the significant associations into 145 unique genomic regions (of at least 1,000,000 base pairs each), and validated the regions by comparing them with prominent gene panels used in the clinics and catalogues of cancer driver genes.

**Figure 3.** External evidence supporting the cancer predisposition regions. Partitioning of the 145 significant cancer genomic regions according to which method found them (GWAS, PWAS or both) and supporting evidence (overlap with clinical cancer gene panels, driver cancer genes, both, or none).

papillomavirus-positive cervical cancer\textsuperscript{42}, and it has also been implicated with prostate and other cancers\textsuperscript{43–45}.
However, E6AP hasn’t been linked to pancreatic cancer, an association that we observe here (PW AS q-value = 8E−04). Another example is AVP (arginine vasopressin; also known as ADH), a gene producing a hormone involved in water balance homeostasis and complex behavioral traits46. Despite vast literature about the hormone, there doesn’t appear to be any direct evidence linking the gene to cancer or specifically to melanoma, as observed here (PW AS q-value = 9E−04).

Functional damage to coding genes is often associated with reduced cancer risk. An advantage of PW AS is that it provides clear interpretation of the directionality of significant associations, namely whether gene damage is associated with elevated or reduced cancer risk. Of the 14 solitons, which are high-confidence PW AS associations, 8 genes (57%) are associated with elevated and 6 (43%) are associated with reduced cancer risk (Table 1). For example, CTLA4 (also known as CD152) is an immune checkpoint and a preferred target in cancer immunotherapy. Reduced CTLA4 function, either through natural genetic variation or immunotherapy treatment, activates T cells and suppresses tumor (while, on the downside, increases the risk for autoimmunity)47. Therefore, it is not surprising that CTLA4 is characterized by PW AS as a protective gene, with gene damage being associated with reduced cancer prevalence in the UKB cohort.

The characterization of genes as being associated with elevated or reduced cancer risk according to PW AS is based on either the dominant or recessive effect scores calculated by the method, depending on the heritability found significant for each association. Notably, the 4 soliton genes showing both dominant and recessive inheritance (potentially with different effect sizes and significance levels) all exhibit consistent trends. In other words, when estimated damage to these genes is associated with elevated (or reduced) cancer risk according to the dominant model, it shows the same trend according to the recessive model.

Across all 110 significant PW AS associations we observe similar patterns, with 62 (56%) being associated with elevated cancer risk and the other 48 (44%) with reduced risk. Among the 16 PW AS associations that are significant for both dominant and recessive effects, 15 show consistent directionality and only one association shows opposite trends between the dominant and recessive models.

Genetic signal varies between cancers. The uniformity of the UKB as a prospective cohort that covers all major cancer types provides a unique opportunity to perform a comparative analysis between cancer types. We start by considering the number of significant genomic regions recovered in each cancer type, according to GW AS, PW AS or both (Table 2). We observe that the number of recovered regions vary substantially across cancer types, ranging from 2 in epithelial ovarian cancer to 58 in non-melanoma skin cancer. As statistical power is determined by sample sizes, it is not surprising that cancers with fewer cases tend to recover fewer significant regions. However, this is not the only factor. Chronic lymphocytic leukemia, for example, has the fewest cases (764), yet it recovers 20 significant regions, more than many other cancers. This could be explained by a strong polygenic signal associated with leukemia, or more likely, it could be a spurious effect of mistaking somatic mutations as germline variants in blood cancers (as UKB genotypes are based on blood samples)48. Colorectal cancer includes 3351 cases but only 4 recovered regions, compared for example to melanoma with 14 recovered regions, despite its slightly lower number of cases (3122). Interestingly, although pan-cancer has the highest

| Gene   | Chromosome bands | Significant cancer types | Lowest PWAS FDR q-value | Lowest GWAS p-value | PWAS heritability | Protein damage associated with cancer risk (R) or protection (P) | External evidence (out of the 2 gene panels and 3 cancer driver catalogues) |
|--------|------------------|--------------------------|-------------------------|----------------------|------------------|----------------------------------------------------------------|----------------------------------------------------------------------------------|
| MUTIL | 1p34.1           | Colorectal               | 2E−7                    | 1E−3                 | Recessive        | R                                                              | CleanPlex, Invitae, Census                                                        |
| CTLA4 | 2q33.2-q33.3     | Skin                     | 4E−6                    | 2E−13*               | Both             | P                                                              | CleanPlex                                                                         |
| MITF  | 3p14.1-p13       | Melanoma                 | 1E−8                    | 4E−4                 | Both             | R                                                              | CleanPlex, Invitae, Census                                                        |
| SLC4A2 | 5p13.3-p13.2     | Skin, melanoma, P-C      | 1E−20                   | 4E−22*               | Recessive        | R                                                              | None                                                                              |
| CCDC170| 6q25.1-q25.2     | Breast                   | 5E−5                    | 1E−13*               | Dominant         | R                                                              | None                                                                              |
| POUSF1B| 8q24.21          | Prostate, P-C, colorectal | 4E−22                   | 4E−42*               | Both             | P                                                              | None                                                                              |
| MTAP  | 9p21.3           | Skin, melanoma, P-C      | 1E−4                    | 8E−23*               | Both             | P                                                              | None                                                                              |
| STN1  | 10q24.33-q25.1   | P-C, melanoma            | 9E−6                    | 3E−10*               | Recessive        | P                                                              | None                                                                              |
| UBE3A | 15q11.2-q12      | Pancreatic               | 8E−4                    | 3E−4                 | Recessive        | R                                                              | None                                                                              |
| HOXB13| 17q21.32         | Prostate, P-C            | 2E−31                   | 6E−40*               | Dominant         | R                                                              | CleanPlex, Invitae                                                               |
| IGF3  | 19q13.33         | Skin                     | 7E−6                    | 1E−6                 | Dominant         | R                                                              | None                                                                              |
| KLK3  | 19q13.33-q13.41  | Prostate                 | 4E−9                    | 3E−25*               | Dominant         | P                                                              | None                                                                              |
| AVP   | 20p13            | Melanoma                 | 9E−4                    | 2E−4                 | Recessive        | P                                                              | None                                                                              |
| CHEK2 | 22q12.1-q12.2    | Breast, P-C, prostate    | 5E−5                    | 3E−6                 | Dominant         | R                                                              | CleanPlex, Invitae, Census, PanSoftware, FABRIC                                   |

Table 1. Soliton cancer genes discovered by PWAS. *Below the GWAS exome-wide significance threshold (5E−07); P-C, Pan-cancer.
Table 2. Studied cancer types.

| Cancer type                  | ICD-10 codes          | Sex | # samples | # cases | # controls | # significant GWAS regions | # significant PWAS regions | # total significant regions |
|-----------------------------|-----------------------|-----|-----------|---------|------------|---------------------------|---------------------------|-----------------------------|
| Pan-cancer                  | C00-C26, C30-C34, C37-C58, C60-C86, C88, C90-C97 | All | 274,830   | 56,634  | 218,196    | 19                        | 12                        | 26                          |
| Breast cancer               | C50                   | F   | 149,186   | 10,682  | 138,504    | 17                        | 2                         | 18                          |
| Chronic lymphocytic leukemia| C91                   | All | 274,830   | 764     | 272,079    | 4                         | 16                        | 20                          |
| Colorectal cancer           | C18                   | All | 274,830   | 3351    | 271,479    | 1                         | 4                         | 4                           |
| Epithelial ovarian cancer   | C56                   | F   | 149,186   | 1112    | 147,944    | 2                         | 0                         | 2                           |
| Lung cancer                 | C34                   | All | 274,830   | 2479    | 272,351    | 3                         | 4                         | 6                           |
| Melanoma                    | C43                   | All | 274,830   | 3122    | 271,708    | 8                         | 12                        | 14                          |
| Non-melanoma skin cancer    | C44                   | All | 274,830   | 18,944  | 255,886    | 43                        | 27                        | 58                          |
| Pancreatic cancer           | C25                   | All | 274,830   | 768     | 264,559    | 3                         | 2                         | 5                           |
| Prostate cancer             | C61                   | M   | 125,644   | 7438    | 118,206    | 30                        | 8                         | 32                          |

Predisposition genomic loci are mostly cancer-type specific. We also consider the extent to which cancer predisposition genetic signal overlaps between cancers, by counting the number of significant cancer regions shared between cancer types (Fig. 5). For example, melanoma and non-melanoma skin cancer share a substantial genetic signal, with 7 of the 14 melanoma regions being also significant in non-melanoma skin cancer (Fig. 5B). A shared genetic signal between these two cancer types is expected, given their relatedness. More surprising is the fact that 3 of the 18 breast-cancer regions are shared with prostate cancer (with overall 32 regions), while none of the 2 significant ovarian-cancer regions is shared with breast cancer (or any other cancer type). One of the 3 genomic regions shared between breast and prostate cancer is found in 11q13.3. Most significant in this region is the intergenic variant rs7130881 (lowest GW AS p-value = 2E−53 in melanoma), which plays a central role in skin pigmentation, melanin formation and melanocyte differentiation. Many variants in the gene have been associated with pigmentation differences and elevated risk of skin cancer and melanoma. Additional major pigmentation-related genes identified in this study include TYR (tyrosinase; PW AS q-value = 6E−13 in non-melanoma skin cancer and q-value = 0.005 in melanoma) and SLC45A2 (solute carrier family 45 member 2; PW AS q-value = 1E−20 in melanoma).
in that region is rs2849691 (lowest GWAS \( p \)-value = 6E−13) that occurs in the non-coding lncRNA transcript LOC107985478. The other region, 6p22.1-p21.31, is a 4.7 Mbp genomic region covering the MHC region. Of the 138 genes in that region, 7 are significant in non-melanoma skin cancer according to PWAS: HLA-DPA1, HLA-C, PPP1R18, CCHCR1, MPIG6B, MUC22 and C6orf15 (Supplementary Table S1).

Other than the handful of shared regions mentioned here, most cancer types show little overlap with other cancers (Fig. 5). Overall, of the 145 cancer predisposition regions, only 27 are shared by multiple cancers. Disregarding pan-cancer, only 14 regions are shared by two or more specific cancer types.

**Recessive effects are prevalent in cancer predisposition.** Unlike GWAS, PWAS explicitly models dominant and recessive effects at the gene level and has the capacity to capture genetic effects that transcend the individual variant. It therefore provides the opportunity to assess the importance of these effects to cancer predisposition. We observe that recessive effects are indeed common among significant PWAS regions, and especially among the regions that are not captured by GWAS (Fig. 6A). The enrichment of recessive effects in

---

**Figure 4.** Genome-wide cancer predisposition in breast, lung and non-melanoma skin cancer. Manhattan plots for three selected cancer types. The plots show the significance of all the variants and genes tested with GWAS and PWAS. \( p \)-values are capped at 1E−15. Similar Manhattan plots for all ten cancer types (including pan-cancer) are available in Supplementary Fig. S1.
Figure 5. Number of significant regions per cancer-type combination. (A) Venn diagram of the 18 significant genomic regions in breast cancer and the 32 significant regions in prostate cancer with 3 overlapping regions between these two cancer types, as an example of the unique and shared genetic signals between cancer types. (B) Partitioning of the 145 significant cancer genomic regions by the combination of cancer types in which they were found significant. Each node in the graph represents a combination of cancer types. Two nodes are connected when one combination is a direct subset of the other. Each node is labeled with two numbers: the number of significant regions matching the exact combination of cancer types represented by the node (e.g. 12 genomic regions that are unique to breast cancer), and the total number of significant regions matching any combination of cancer types that includes this combination (e.g. overall 18 regions associated with breast cancer, including 6 regions shared with other cancers). Node sizes reflect the number of significant regions that match the combinations exactly. Nodes representing combinations of more than one cancer type are colored dark blue. Pan-cancer is abbreviated as P-C.
Figure 6. Dominant and recessive gene effects. (A) Partitioning of the significant cancer genomic regions that are PWAS-significant according to their inheritance mode (dominant, recessive or both), and whether they are also significant by GWAS. (B) GWAS and PWAS p-values (capped at 1E-15) across all 145 significant cancer genomic regions. Regions are color coded by whether they were found significant by the dominant model of PWAS, the recessive one, both, or none. (C) Three examples of significant PWAS associations: MITF and melanoma, HOXB13 and prostate cancer, and SLC45A2 and non-melanoma skin cancer. The plots show how risk for the relevant cancer types changes as a function of PWAS effect scores in the UKB cohort. Dominant effect scores (orange) aim to capture the likelihood of an individual to have at least one damaged copy of the gene, whereas recessive effect scores (purple) aim to capture the likelihood of at least two damaged copies. In both types of PWAS effect scores, lower scores reflect individuals with greater gene damage. The line plots show a continuous partitioning of the cohort according to the dominant or recessive effect scores on the x-axis, and the estimated fraction of individuals with a history of the relevant cancer in each partition on the y-axis. For example, in the association between melanoma and the dominant effect scores of MITF (shown on the upper-left plot in (C)), “Bottom 0.5%” on the x-axis refers to the 0.5% of the cohort with the lowest dominant effect scores, namely the 0.5% of individuals that are the most likely to have at least one damaged copy of MITF. The prevalence of melanoma in that group is estimated at ~2%. The dashed horizontal line shows the baseline cancer risk across the entire cohort (1.14% cases for melanoma). The bar plots show the most significant partitioning of individuals. For example, among the 0.9% (2,372) of the individuals with the lowest dominant effect scores calculated for the MITF gene, 61 (2.57% of them) have had melanoma, compared to 1.12% rate of melanoma among the other individuals (3055 melanoma cases among 271,849 individuals). Note that the scales of the plots are not uniform. In particular, each plot shows a different partitioning of the cohort (based on the relevant distribution of effect scores).
PWAS-exclusive regions is explained by the fact that GWAS (under standard settings) models additive genetic effects. Unlike dominant effects, which can be approximated by an additive model, recessive effects cannot be effectively recovered by an additive GWAS model. The same trend shows when considering the evidence for each genomic region according to continuous p-values: significant regions with little evidence according to GWAS tend to be recovered by the recessive model of PWAS (Fig. 6B).

To illustrate the dominant and recessive genetic effects captured by PWAS, we selected three soliton associations with strong effects (see Table 1): MITF (melanocyte inducing transcription factor) associated with melanoma (q-value = 1E−08; both dominant and recessive effects are significant), HOXB13 (homeobox B13) associated with prostate cancer (q-value = 2E−31; only dominant effect is significant) and SLC45A2 (solute carrier family 45 member 2) associated with non-melanoma skin cancer (q-value = 1E−20; only recessive effect is significant). For each of the three associations, we plot cancer risk among UKB individuals as a function of PWAS effect scores (Fig. 6C). PWAS effect scores are assigned to each individual in the cohort with respect to each studied protein-coding gene based on their genotype. They reflect the overall estimated functional damage affecting genes at the molecular level, with lower effect scores reflecting more damage. For each individual, each coding gene is assigned two effect scores that aggregate all the variants within the gene that were genotyped or imputed for that individual: a dominant effect score (reflecting the likelihood of at least one damaging hit) and a recessive effect score (reflecting the likelihood of at least two damaging hits). These effect scores are used by PWAS to detect significant genes (if they correlate with a history of cancer), and they can also be used to assess individual-level risk (with respect to specific genes).

In the case of MITF, we observe that among the 2,372 individuals with the lowest dominant effect scores (comprising 0.9% of the cohort), 61 (2.57% of that group) have had melanoma, compared to only 1.12% risk of melanoma in the rest of the cohort (leading to observed risk-ratio of 2.3). When considering recessive effect scores, we find that 2 out of the 3 individuals with the lowest scores have had melanoma. We conclude that individuals with functional damage to the MITF protein have substantially higher rates of melanoma. As the name of the gene suggests, MITF is a transcription factor that controls the development and function of melanocytes, which are pigment-producing cells. The causal connection of MITF to melanoma is well established.

Unlike MITF, showing both dominant and recessive effects (which might be interpreted as approximating an additive effect), HOXB13 shows a clear dominant effect according to PWAS. Among the 479 males with the lowest dominant effect scores (0.4% of the male cohort), 99 of them (20.7%) have a history of prostate cancer, compared to 5.87% rate of prostate cancer in the rest of the male cohort (risk-ratio of 3.5). HOXB13 regulates cellular response to androgen, an important male hormone. Its link to prostate cancer and early onset of the disease has been established in both GWAS and family studies.

A clear recessive effect is exemplified by SLC45A2 (also known by the names AIM1, MATP and OCA4). Among the 13,196 individuals with highest recessive effect scores, i.e. the 5% of the UKB cohort least likely to have two damaged copies of the gene, 648 of them (4.91%) are cases of non-melanoma skin cancer, compared to 6.99% of cases in the rest of the cohort (risk-ratio of 1.4). SLC45A2 is a transporter protein likely involved in the production of melanin. The gene has indeed been implicated in melanoma and skin cancer through albinism, a disorder known for recessive inheritance.

These three examples demonstrate the applicability of PWAS effect scores to clinical risk assessment. Similar plots for all 110 significant PWAS associations are available in Supplementary Fig. S2.

To further examine the recessive associations, we list the 30 genomic regions with only significant recessive effects (Fig. 6A) in Table 3 (full summary statistics for these and all other significant regions are available in Supplementary Table S1 and Supplementary Table S3). We find that 29 of the 30 recessive regions support exactly one significant association of gene and cancer-type, and we therefore identify the regions by the significant genes (the only exception is the region of SEMA3F on chromosome 3, in which another gene, MST1R, is also significant, but less so). Notably, 9 of the 30 recessive genes are enzymes (or part of enzyme complexes), which are considered a standard model for recessive effects. Additional 4 genes are transporters associated with the solute carrier family (or regulators of such transporters). In fact, of all 110 significant PWAS associations, these genes are the only transporters of that family (namely, 4 genes associated with the solute carrier family that we have recovered exhibit pure recessive effects). Both SLC12A9 and SLC45A2, which we associate with melanoma and non-melanoma skin cancer, are implicated with pigmentation according to the Open Targets Platform.

We also observe that many of the 30 recessive genes are involved in cellular processes of apoptosis, ubiquitination and immunology. Interestingly, leukemia seems to be particularly enriched with recessive effects. Of the 16 genomic regions associated with leukemia according to PWAS, 12 show exclusive recessive effects and are listed in Table 3. The possibility of missing somatic mutations as germline variation in blood cancers should be taken into account when interpreting this finding. For example, the high prevalence of recessive heritability in leukemia might be a reflection of the “second-hit” hypothesis. As an external validation scheme, Table 3 also lists published cancer genetic associations curated by the Open Targets Platform. We find that the cancer types reported by the Open Targets Platform are usually in agreement with our results. Nevertheless, most recessive genes appear to represent novel genetic associations, maybe as a result of recessive genetic studies being largely neglected in case–control cohorts. When considering the external validation used earlier (Fig. 3), only 2 of the 30 recessive genes are supported by clinical panels or catalogues of cancer drivers. Specifically, MUTYH and BRC3 are both established as cancer drivers, and they both appear in clinical panels. Overall, these 30 recessive genes highlight the importance of modeling recessive inheritance in non-familial (case–control) cancer studies.
Discussion

We performed a comprehensive analysis of cancer predisposition in the UKB cohort and identified 145 significant genomic regions by combining both GWAS and PWAS. The two methods complemented each other. While GWAS identifies variants with additive genetic effects, PWAS identifies coding genes with dominant or recessive effects (or a combination of these effects).

The capacity of PWAS to detect non-additive effects has proven substantial in our analysis. We detected 30 genomic regions with pure recessive effects, indicating that recessive inheritance is substantial for cancer predisposition also outside of family studies. Many of the discovered genes with significant recessive effects had not been previously implicated with cancer predisposition (Table 3), indicating that non-additive effects are neglected in contemporary genetic association studies. The main reason for the scarcity of studies on recessive effects is that GWAS and current variant-level methods are not designed to capture such genetic effects, especially when compound heterozygosity is involved. By exposing the importance of recessive inheritance to cancer predisposition and presenting a methodology for recovering it, we aim to motivate future investigation of this underexplored source of cancer risk (and of other conditions).

Many of the genomic loci recovered in this study are supported by external evidence (clinical panels and cancer drivers), while many are novel associations (Fig. 3, Table 3). While proving definite causal links is beyond the scope of this work, many of our novel discoveries appear as promising candidates. In particular, genes defined as solitons (Table 1) are likely less sensitive to linkage-disequilibrium and are therefore more likely to prove causal.

Many of the reported genes are associated with substantial cancer risk (Fig. 6C). For example, we show that individuals in the male cohort with substantial damage to HOXB13 have an increased risk of prostate cancer (20.7%, compared to 5.9% in the rest of the male cohort). We provide a similar cancer risk analysis for all 110 PWAS gene associations (Supplementary Fig. S2). The capacity for risk assessment at the resolution of whole

| Gene symbol | Gene name | Chromosome bands | Molecular function | Cancer type | Cancer genetic associations according to open targets platform |
|-------------|-----------|------------------|-------------------|------------|----------------------------------------------------------|
| PAD1i       | Peptidyl Arginine Deiminase 1 | 1p36.13          | Enzyme            | Melanoma   | None                                                     |
| AKIRIN1     | Akirin    | 1p34.3-p34.2     | Regulator         | Lung       | None                                                     |
| MUTYH       | Adenine DNA glycosylase | 1p34.1          | Enzyme            | Colorectal | Colorectal and other cancers                            |
| FCGR1A      | High affinity immunoglobulin gamma Fc receptor 1 | 1q21.2         | Receptor          | Leukemia   | None                                                     |
| OR6K6       | Olfactory receptor 6K6 | 1q23.1-q23.2    | Receptor          | Pancreatic | None                                                     |
| DPT         | Dermatopentin | 1q24.2         | ECM               | Leukemia   | Leukemia                                                 |
| TNFSF18     | Tumor necrosis factor ligand superfamliy member 18 | 1q24.3-q25.1   | Cytokine          | Leukemia   | None                                                     |
| XPC         | DNA repair protein complementing XP-C cells | 3p25.1          | DNA binding       | Skin       | Skin                                                     |
| LYZL4       | Lysozyme-like protein 4 | 3p22.1         | Enzyme            | Leukemia   | None                                                     |
| SEMA3F      | Semaphorin-3F | 3p21.31-p21.2   | Chemotaxis        | Skin       | None                                                     |
| POLR2H      | DNA-directed RNA polymerases I, II, and III subunit RPABC3 | 3q27.1-q27.2   | Enzyme            | Melanoma   | None                                                     |
| RCHY1       | RING finger and CBY zinc finger domain-containing protein 1 | 4q13.3-q23.1   | Enzyme            | Leukemia   | None                                                     |
| PCDH10      | Protocadherin-10 | 4q28.3         | Cell adhesion     | Leukemia   | None                                                     |
| SLC45A2     | Membrane-associated transporter protein | 5p13.3-p13.2   | Transporter       | Skin       | Skin and melanoma                                        |
| PTPN12      | Tyrosine-protein phosphatase non-receptor type 12 | 7q11.23-q21.11 | Enzyme            | Skin       | None                                                     |
| LMTK2       | Serine/threonine-protein kinase LMTK2 | 7q21.3-q22.1   | Enzyme            | Prostate   | Prostate                                                 |
| SLC12A9     | Solute carrier family 12 member 9 | 7q22.1          | Transporter       | Melanoma   | Skin                                                     |
| STN1        | CST complex subunit STN1 | 10q24.33-q25.1 | DNA binding       | Pan-cancer | Many cancers                                              |
| BIRC3       | Baculoviral IAP repeat-containing protein 3 | 11q22.1-q22.2  | Regulator         | Leukemia   | Leukemia and other blood cancers                         |
| JDP2        | Jun dimerization protein 2 | 1q24.3         | Regulator         | Skin       | Leukemia                                                 |
|UBE3A        | Ubiquitin-protein ligase E3A | 15q11.2-q11.2  | Enzyme            | Pancreatic | Leukemia                                                 |
| SLC12A6     | Solute carrier family 12 member 6 | 15q14          | Transporter       | Lung       | None                                                     |
| STX8        | Syntaxin-8 | 17p13.1         | Receptor          | Melanoma   | None                                                     |
| ATPF2       | ATP synthase mitochondrial F1 complex assembly factor 2 | 17p11.2        | Enzyme complex    | Lung       | None                                                     |
| AVP         | Vasopressin-neurophysin 2-coppeptin | 20p13          | Hormone           | Melanoma   | None                                                     |
| SLC2A4RG    | SLC2A4 regulator | 20q13.33       | Regulator         | Prostate    | Prostate and other cancers                               |
| CCT8        | T-complex protein 1 subunit theta | 21q21.3        | Chaperone         | Leukemia   | None                                                     |
| SGS5M       | Small G protein signaling modulator 3 | 22q13.1-q13.2  | Regulator         | Leukemia   | Breast                                                   |
| RBMX2       | RNA-binding motif protein, X-linked 2 | 4q25.1-q26.1   | RNA binding       | Leukemia   | None                                                     |
| ZNF449      | Zinc finger protein 449 | 4q25.1-q26.1   | DNA binding       | Leukemia   | None                                                     |

Table 3. Recessive cancer predisposition genes.
genes is enabled by PWAS through the aggregation of all variants affecting an individual. Integration of such data into the clinics could have a substantial impact on individual and familial cancer risk evaluation. Even when variants of unknown significance are observed after the initial study, PWAS can still estimate gene damage and compare it to the population distribution, thereby providing risk assessment.

The presented analysis was conducted over nine specific cancer types and pan-cancer. We observe that most cancer predisposition loci are cancer-type specific. Only 14 of the 145 loci are shared by two or more specific cancer types, with 7 of them shared only by melanoma and non-melanoma skin cancer. Only 2 loci are shared by three or more specific cancer types (Fig. 5). The pan-cancer analysis recovered only 3 unique associations not discovered in specific cancers. This observation is in stark contrast to somatic tumor genomics, where most discovered cancer drivers are pan-cancer⁶⁰. Our results suggest that cancer predisposition of germline genetic variation, unlike positive selection of somatic mutations in tumors, are mostly cancer-type specific. The cancer type with the highest number of recovered loci is non-melanoma skin cancer, with 58 of the 145 genomic regions associated with that cancer type. While this could be explained by the high number of cases for that cancer type, it highlights a substantial polygenic signal for non-melanoma skin cancer. Such strong polygenicity is compatible with the substantial role of environmental factors such as UV radiation and viral infection in this cancer⁶⁴.

An important limitation of our analysis is its restriction to the white British population, as the UKB cohort does not include a substantial number of individuals from other ethnicities required for sufficient statistical power (see Methods). This leads to a lack of validation of the discovered associations on other populations, as well as oversight of additional associations only present in other ethnic groups. Another limitation of the UKB is the lack of sequencing data for the vast majority of the cohort. In this analysis we relied solely on genotyping of ~ 800 K predefined genetic markers and ~ 600 K variants in coding regions imputed from the original set of markers ⁶⁲. This limitation is particularly relevant for PWAS, which underestimates genetic damage when non-genotyped variants are involved, leading to diminished statistical power (but, critically, not to false discoveries)⁶³.

This study demonstrates the power of exhaustive genomic and protein-centric analysis over large biobanks for expanding the discovery of cancer predisposition loci beyond family studies. In particular, we have demonstrated that recessive effects are also prevalent in case–control cohorts when looked for by suitable methods. We have also demonstrated the benefit of cohorts with diverse cancer-type annotations for cross-cancer comparisons. Finally, our results show promise towards individual clinical risk assessment of cancer.

Methods

Study cohort. From the entire UK Biobank (UKB) cohort of 502,520 individuals (application ID 26664)²⁵,²⁶, we filtered out 227,690 individuals (see Fig. 2) for the following reasons: i) 14 individuals had asked to withdraw from the UKB, ii) 92,922 were non-whites (according to self-reported ethnicity or their genetics), iii) 312 had self-reported sex mismatching their genetics, iv) 75,848 were family-related to other individuals in the cohort (from each group of related individuals we chose only one representative), and v) 58,594 didn’t have any recorded ICD-10 codes (which were required to determine cancer history).

Following these filtrations, we remained with a study cohort of 274,830 individuals, 56,634 (20.06%) of them had a history of cancer according to their ICD-10 codes (the number of cases and controls per cancer type are listed in Table 2).

In addition to cancer status, we also extracted from the UKB the following set of covariates: sex, year of birth, 40 genetic principal components (PCs), genotyping batch (105 categories) and UKB assessment center (25 categories). Altogether, 173 covariates (including a constant intercept) were included in the GWAS and PWAS analyses. We chose using 40 PCs, which is the maximal number of PCs provided by the UKB, to minimize the risk of false discoveries due to unaccounted population structure (at the cost of slightly reduced statistical power).

While this work would clearly benefit from trans-ethnic analysis (in particular, validation of the reported associations on independent cohorts of other ethnicities)⁶⁵, the UKB does not include a sufficient number of samples from any non-white ethnic group to support such analysis. The largest minority group in the UKB is the Indian group which includes ~ 6000 samples. Such sample size is sufficient in the presence of continuous traits or very common binary traits, but not binary traits with a prevalence of 1–2% (which is the typical prevalence of most cancer types; see Table 2). Specifically, a sample size of ~ 6000 and a disease prevalence smaller than 2% entails only up to ~ 100 cases. In other words, under such settings, the number of events would be smaller than the number of variables (having 173 covariates), while PLINK recommends at least 10 events per variable⁶⁶.

The computational pipeline for processing the UK Biobank data used in this work is an open-source project available at https://github.com/nadavbra/ukbb_parser.

GWAS. To run GWAS, we used the PLINK software⁶⁶ (https://www.cog-genomics.org/plink/2.0/; version v2.00a2.3ML 64-bit Intel, 24 Jan 2020). For example, to run GWAS for breast cancer over chromosome 1, we ran the following command:

```
plink2 --glm --bed ukb_cal_chr1_v2.bed --bim ukb_snps_chr1_v2.bim --fam ukb2666_cal_chr1_v2_s488366.fam --pheno breast_cancer.txt --covar covariates.txt --out chr1_breast_cancer --1 hide-covar no-x-sex --mac 20 --covar-variance-standardize --freq --threads 32 --memory 100000.
```

Where `ukb_cal_chr1_v2.bed`, `ukb_snps_chr1_v2.bim` and `ukb2666_cal_chr1_v2_s488366.fam` are the files with the genetic data of chr1, provided by the UKB. The files `breast_cancer.txt` and `covariates.txt` are PLINK-formatted tab-separated data files with the cancer phenotype (case-control status) and covariates of each of the samples in the study cohort, respectively. The `--glm` argument specifies the use of a linear/logistic model; the `--1` flag specifies that cases and controls are encoded as 1 and 0, respectively; the `hide-covar` flag indicates that summary statistics are to be reported only with respect to the phenotype (but not the individual covariates); the no-x-sex flag indicates that sex is not to be re-added as a covariate (since it’s already included among the provided covariates).
7049 variants genotyped by the UKB (223 of which are GW AS-significant) and 138 protein-coding genes tested overlapping genomic loci of sizes of at least 1Mbp, available in Supplementary Table S1. The largest obtained coordinate of the start codon to the last before the stop codon). This merging procedure resulted in 145 non-overlapping genomic regions of sizes of at least 1Mbp, available in Supplementary Table S1. The method is fully described and validated in a previous work33. In the case of cancer predisposition, PWAS detects protein-coding genes that are significantly more (or less) damaged in individuals with a history of cancer. To determine to what extent a given gene is damaged within a given individual (based on his or her genetics), PWAS employs a machine-learning model that assigns functional effect score to each variant affecting the coding sequence of the gene. Specifically, PWAS uses the FIRM predictor, a random-forest classifier that assigns each variant a score reflecting the probability of the gene to retain its function in the presence of that variant36. FIRM relies on 1109 numerical features capturing the rich proteomic context of the gene and the affecting variant. The main features included in FIRM are: (i) the location of the variant within the protein sequence, (ii) the reference and alternative amino acids, (iii) amino-acid scales (i.e. various numeric values assigned to amino acids, in different contexts of the protein and the variant); (iv) protein annotations extracted from UniProt67 (e.g. secondary structure, post-translational modifications, functional sites, etc.), and (v) Pfam domain and clan annotations68 (e.g. whether the variant is within or next to a domain). Following the assignment of effect scores to individual variants, PWAS aggregates the effect scores of all variants in the coding sequence of the gene (in the context of the individual’s genetics). Specifically, it calculates dominant and recessive effect scores which reflect the probabilities for at least one or at least two damaging events in the gene, respectively. Finally, PWAS tests whether the dominant and recessive effect scores of the gene are significantly different between cases and controls. Under the combined model (for which both dominant and recessive scores are zero when fitting a logistic regression model to explain cancer status. In other words, a significant PWAS association indicates that at least one of the two effect scores (or some linear combination of them) is associated with cancer predisposition.

We used version 1.0.4 of the PWAS software (available at https://github.com/nadavbra/pwas) and executed the standard PWAS pipeline (as specified on that GitHub page). We derived the dominant and recessive PWAS effect scores for the entire UKB cohort (which depend solely on the genetic information) and tested associations between 18,053 protein-coding genes and the ten cancer phenotypes. The complete PWAS results with full summary statistics, which include 110 FDR-significant gene-cancer associations, are available per cancer type in Supplementary Table S3.

Multiple testing correction. We accounted for multiple testing by using the accepted exome-wide significance threshold ($p < 5 \times 10^{-7}$) in GWAS, and false discovery rate (FDR) with the standard significance threshold ($q < 0.05$) across all 18,053 tested genes in PWAS. Nonetheless, some interpretations of our results may warrant stricter significance threshold. First, the genome-wide significance threshold ($5 \times 10^{-8}$) is more appropriate when considering non-exonic regions by GWAS. Second, as our analysis considers ten different cancer types, another factor of 10 in the significance threshold might be justified (e.g. 0.005 instead of 0.05 in PWAS). On the other hand, if one considers only a specific cancer type of interest, then this would not be unnecessary. A conservative interpretation of our results may warrant further division of the significance threshold by another factor of 2, to account for the fact that both GWAS and PWAS have been used (even though this might be somewhat too conservative, as the two methods are applied over the same data and are not completely independent). As always, $p$- and $q$-values are best interpreted as continuous measures of statistical evidence rather than dichotomous markers of significance. A prudent interpretation of statistical analysis should always consider their exact values, and not only whether or not they are below a certain threshold. Due to the considerations outlined here, GWAS results with $p$-values between 2.5E–09 and 5E–07 and PWAS results with $q$-values between 0.0025 and 0.05 may be seen as borderline. To allow easy interpretation of our results and comparison between GWAS and PWAS in exonic regions, we decided to stick with the simple thresholds of $p < 5 \times 10^{-7}$ and $q < 0.05$ throughout this work, while making available the full summary statistics across all regions (Supplementary Table S1), variants (Supplementary Table S2) and genes (Supplementary Table S3).

Merging the significant associations into unique genomic regions. We merged the 883 significant GWAS associations and 110 significant PWAS associations into 145 unique genomic regions by extending each association by 500,000 base-pairs on both sides and iteratively merging overlapping regions. GWAS associations started as 1 bp and were extended into 1,000,001 bp regions (the position of the variant, plus 500,000 bp on each side) while PWAS associations started as the region of the gene's coding-sequence (i.e. from the genomic coordinate of the start codon to the last before the stop codon). This merging procedure resulted in 145 non-overlapping genomic loci of sizes of at least 1Mbp, available in Supplementary Table S1. The largest obtained locus was chr6:30,145,049–34,892,998 (of size 4.7 Mbp), which covers the MHG region. This region contains 7049 variants genotyped by the UKB (223 of which are GWAS-significant) and 138 protein-coding genes tested by PWAS (7 of them are PWAS-significant).
**External cancer evidence.** We validated each of the 145 cancer predisposition regions against three catalogues of cancer drivers (Census\(^34\), pan-software\(^35\) and FABRIC\(^36,37\)) and two gene panels used in the clinics (CleanPlex TMB 500 and Invitae Multi-Cancer). The “Cancer Gene Census” was downloaded as a CSV file (cancer_gene_census.csv, from https://cancer.sanger.ac.uk/cosmic/download) containing 723 genes. Each of the Census genes is identified as a tumor-suppressor gene (TSG), oncogene or a fusion gene (or any combination of these three categories). The list of 515 genes in the CleanPlex TMB 500 panel was downloaded from https://www.paragogenomics.com/wp-content/uploads/2019/04/PS1008_CleanPlex_TMB-500-Panel_Gene-List.txt, and the list of 83 genes in the Invitae Multi-Cancer panel was downloaded from https://www.invite.com/en/physician/tests/01101/info-panel-essay_information. The list of 83 Invitae Multi-Cancer genes was further extended by 50 extra genes, contributed by Vardi Meiner from the Center for Clinical Genetics in Hadassah Medical Center (Supplementary Table S4). The Census gene list was downloaded in May 2020, and the two panel gene lists were downloaded in June 2020. The list of 299 pan-software driver genes was downloaded from Supplementary Table S1 of the publication\(^35\). The list of 593 FABRIC driver genes was downloaded from Supplementary Table S1 of the publication\(^46\). We mapped the obtained lists of genes onto our 18,053 analyzed genes according to their UniProt ID (in the case of FABRIC) or gene symbols (in the case of the other resources). For each of the 145 genomic regions listed in Supplementary Table S1, we include all the genes in the region that are supported by each of these external catalogues.

In Fig. 3, we consider a genomic locus to be supported by clinical panels or driver catalogues if it contains at least one gene listed in those external resources. In Table 1 and Table 3, we consider the external evidence to be relevant only if it matches the exact gene listed on the table.

In Table 3 we also include cancer associations of the listed genes according to the Open Targets Platform\(^62\). We consider a reported association to be relevant only if (i) it is related to cancer or neoplasm, and (ii) it is supported by genetic association (as opposed to the overall association score reported by the platform, which also includes other sources of evidence, including somatic mutations).

**Determining whether PWAS-estimated gene damage is associated with elevated or reduced cancer risk.** In Table 1 we indicate for each of the genes recovered by PWAS whether estimated protein damage is associated with cancer risk or protection, based on the signs the Cohen's d summary statistics reported by PWAS. Cohen's d is the (normalized) difference in mean gene effect score between cases and controls (calculated independently for both dominant and recessive effect scores). When negative, it indicates that cases have a lower mean effect score (i.e. more gene damage) compared to controls, meaning that gene damage is associated with elevated cancer risk. Conversely, a positive Cohen's d indicates that gene damage is associated with reduced risk.

**Cancer risk as a function of PWAS effect scores.** In Fig. 6C and Supplementary Fig. S2 we illustrate the potential clinical utility of PWAS associations by plotting the risk for the relevant cancer types as a function of dominant and recessive effect scores (which capture the overall amount of gene damage to the relevant gene, per individual). The underlying data for these figures (cancer case–control status and PWAS effect scores) was taken directly from the study cohort (see the relevant sections in the Methods). In the continuous line plots, we examine the entire distribution of PWAS effect scores by considering all possible cutoffs of the relevant cohort, i.e. all subsets with effect scores that are either below or above a certain threshold. Since the precise effect-score values are not very informative, we describe the relevant sub-populations by percentiles (e.g. “bottom 0.9%”, referring to the 0.9% of the cohort with the lowest scores, namely the 0.9% with the greatest estimated functional damage to the gene, or “top 5%, referring to the 5% of the cohort with the highest scores, namely the 5% with the least estimated functional damage to the gene). Each of the continuous plots also includes a reference to the entire cohort, marked on the x-axis as “All”. Cutoffs of bottom percentiles are shown to the left of the entire-cohort reference point, and cutoffs of top percentiles are shown to its right (both in log scale). On the y-axis of these plots we show the estimated prevalence of the relevant cancer type in the study cohort. Note that the estimated cancer prevalence is not the naive fraction of individuals who were diagnosed with the relevant cancer type (among the group of individuals described by the relevant partition). Rather, it is based on the 95% confidence interval for the fraction of cases in the relevant group, calculated by Wilson score interval’s method for binomial proportion. When the confidence interval overlaps with the baseline cancer rate (the dashed horizontal line in the plot), then the estimated prevalence is taken to be that baseline value. When the entire confidence interval is strictly above or below the baseline rate, then the more conservative bound of the confidence interval (that is closer to the baseline rate) is taken as the estimated prevalence. In other words, when the confidence interval is above the baseline rate, then its lower bound is taken, and when it is below the baseline rate, then its higher bound is taken. By relying on the 95% confidence interval, rather than naive frequency of cases, more reliable estimates are obtained when dealing with small groups at the tails of the distributions (which could show wild random variations due to small numbers).

In addition to the continuous plots that capture the entire distribution of PWAS effect scores, we also illustrate the associations by choosing specific cutoffs showing the strongest differences. Specifically, we tested each cutoff by Fisher’s exact test for the association between the effect-score cutoff to cancer case–control status, selecting the cutoff with the lowest p-value (and display the plot only if it's lower than 1E–03).

Note that these plots do not account for covariates, and should therefore not be considered as rigorous statistical evidence for the associations (unlike the summary p-values reported by PWAS, which account for covariates and consider the entire distribution of effect scores).
References

1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646–674 (2011).
2. Gabai-Kapara, E. et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc. Natl. Acad. Sci. 111, 14205–14210 (2014).
3. Rahman, N. Realizing the promise of cancer predisposition genes. Nature 505, 302–308 (2014).
4. Zhang, J., Nichols, K. E. & Downing, J. R. Germline mutations in predisposition genes in pediatric cancer. N. Engl. J. Med. 374, 1391 (2016).
5. Huang, K. et al. Pathogenic germline variants in 10,389 adult cancers. Cell 173, 355–370 (2018).
6. Rasnic, R., Brandes, N., Zuk, O. & Linial, M. Substantial batch effects in TCGA exome sequences undermine pan-cancer analysis of germline variants. BMC Cancer 19, 1–10 (2019).
7. Mucci, L. A. Familial risk and heritability of cancer among twins in Nordic countries. JAMA 315, 68–76 (2016).
8. Sampson, J. N. et al. Analysis of heritability and shared heritability based on genome-wide association studies for 13 cancer types. Nat. Genet. 47, 299–307 (2015).
9. Jiao, S. et al. Estimating the heritability of colorectal cancer. Hum. Mol. Genet. 23, 3989–3995 (2014).
10. Cerhan, J. R. & Slager, S. L. Familial predisposition and genetic risk factors for lymphoma. Blood 126, 2265–2273 (2015).
11. Esteban-Jurado, C. et al. New genes emerging for colorectal cancer predisposition. World J. Gastroenterol. WJG 20, 1961 (2014).
12. Sud, A., Knippers, B. & Houlston, R. S. Genome-wide association studies of cancer: current insights and future perspectives. Nat. Rev. Cancer 17, 692–704. https://doi.org/10.1038/nrc.2017.82 (2017).
13. Stadler, Z. K. et al. Genome-wide association studies of cancer. J. Clin. Oncol. 28, 4255 (2010).
14. Michailidou, K. et al. Association analysis identifies 65 new breast cancer risk loci. Nature 551, 92 (2017).
15. Fachal, L. & Dunning, A. M. From candidate gene studies to GWAS and post-GWAS analyses in breast cancer. Curr. Opin. Genet. Dev. 30, 32–41 (2015).
16. Bossé, Y. & Amos CI (2018) A decade of GWAS results in lung cancer.
17. Benafif, S., Kote-Jarai, Z. & Eeles, R. A. A review of prostate cancer genome-wide association studies (GWAS). Cancer Epidemiol. Prev. Biomarkers 27, 845–857 (2018).
18. Dai, J. E. et al. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis 33, 1327–1331 (2012).
19. Law, M. H. et al. Genome-wide association identifies five new metastasis loci for colon cancer. Nat. Genet. 47, 987 (2015).
20. Galvan, A., Ioannidis, J. P. A. & Dragani, T. A. Beyond genome-wide association studies: Genetic heterogeneity and individual predisposition to cancer. Trends Genet. 26, 132–141 (2010).
21. Rasnic, R., Linial, N. & Linial, M. Expanding cancer predisposition genes with ultra-rare cancer-exclusive human variations. Sci. Rep. 10, 13462. https://doi.org/10.1038/s41598-020-70494-0 (2020).
22. Farashi, S., Kryza, T., Clements, J. & Batra, J. Post-GWAS in prostate cancer: From genetic association to biological contribution. Nat. Rev. Cancer 19, 46–59 (2019).
23. Campbell, P. J. et al. Pan-cancer analysis of whole genomes. Nature 578, 82–93. https://doi.org/10.1038/s41586-020-1969-9 (2020).
24. Rashkin, S. R. et al. Pan-cancer study detects genetic risk variants and shared genetic basis in two large cohorts. Nat. Commun. 11, 1–14 (2020).
25. Sudlow, C. et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 12, e1001779 (2015).
26. Bycroft, C. et al. Genome-wide genetic data on ~500,000 UK Biobank participants. BioRxiv 166298 (2017).
27. Sanjak, J. S. et al. A model of compound heterozygous, loss-of-function alleles is broadly consistent with observations from complex-disease GWAS datasets. PLoS Genet. 13, e1006573 (2017).
28. Miller, D. B. & Piccolo, S. R. Compound heterozygous variants in pediatric cancers: A systematic review. Front. Genet. 11, 493 (2020).
29. Pakkanen, S. et al. Segregation analysis of 1,546 prostate cancer families in Finland shows recessive inheritance. Hum. Genet. 121, 257–267 (2007).
30. Hemminki, K. & Li, X. Familial risk for lung cancer by histology and age of onset: Evidence for recessive inheritance. Exp. Lung Res. 31, 205–215 (2005).
31. Hemminki, K. & Chen, B. Familial risks for colorectal cancer show evidence on recessive inheritance. Int. J. Cancer 115, 835–838 (2005).
32. Guindo-Martinez, M. et al. The impact of non-additive genetic associations on age-related complex diseases. bioRxiv (2020).
33. Brandes, N., Linial, N. & Linial, M. PWAS: Proteome-wide association study—Linking genes and phenotypes by functional variation in proteins. Genome Biol. 21, 1–22 (2020).
34. Sondka, Z. et al. The COSMIC Cancer Gene Census: Describing genetic dysfunction across all human cancers. Nat. Rev. Cancer 18, 696–705 (2018).
35. Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173, 371–385 (2018).
36. Brandes N, Linial N, Linial M (2019) Quantifying gene selection in cancer through protein functional alteration bias. Nucleic Acids Res.
37. Kelman, G., Brandes, N. & Linial, M. The FABRIC cancer portal: A ranked catalogue of gene selection in tumors over the human coding genome. Cancer Res. 81, 1178–1185 (2021).
38. Duguy, D. et al. In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. Cancer Res. 62, 5148–5152 (2002).
39. Wang, W. et al. Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-$\kappa$B contributes to UV radiation-induced immune suppression. Cancer Res. 79, 2992–2997 (2019).
40. Ding, C. et al. $\beta$-catenin regulates IRF3-mediated innate immune signalling in colorectal cancer. Cell Prolif. 51, e12468 (2018).
41. Wang, S. S. et al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J. Infect. Dis. 199, 20–30 (2009).
42. Beaudoenn, S. & Huibregtse, J. M. HPV E6, E6AP and cervical cancer. BMC Biochem. 9, 1–7 (2008).
43. Gut, T. et al. Proteo transcriptomic measurements of E6-associated protein (E6AP) targets in DU145 prostate cancer cells. Mol. Cell Proteomics 17, 1170–1183 (2018).
44. Raghu, D. et al. E6AP promotes prostate cancer by reducing p27 expression. Oncotarget 8, 42997 (2017).
45. Kohli, S., Bhadwaj, A., Kamari, R. & Das, S. SIRT6 is a target of regulation by UBE3A that contributes to liver tumorigenesis in an ANXA2-dependent manner. Cancer Res. 78, 645–658 (2018).
46. Rotondo, F. et al. Arginine vasopressin (AVP): A review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system. Pituitary 19, 345–355 (2016).
Acknowledgements

We would like to thank Vardiela Meiner from the Center for Clinical Genetics in Hadassah Medical Center for fruitful discussion and valuable feedback on our work. We would also like to thank Roni Rasnic from the Hebrew University for important comments on our manuscript.

Author contributions

N.B. carried out the research and wrote the manuscript. N.L. assisted with the statistical analysis. M.L. led the project and took part in the writing.

Funding

Research was partially supported by the Israel Science Foundation (ISF #2753/20) and Israel Cancer Association (ICR # 20210066) grants to M.L.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-94252-y.

Correspondence and requests for materials should be addressed to M.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2021